Nabriva Therapeutics plc (NBRVF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, Nabriva Therapeutics plc (NBRVF) es una empresa del sector Healthcare valorada en 0. La acción obtiene una puntuación de 57/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 15 mar 2026Nabriva Therapeutics plc (NBRVF) Resumen de Asistencia Médica y Tuberías
Nabriva Therapeutics plc specializes in the development of innovative anti-infective agents, with a strong focus on addressing serious bacterial infections through its proprietary products and ongoing clinical trials.
Tesis de Inversión
Nabriva Therapeutics plc is positioned for potential growth driven by its innovative product pipeline and ongoing clinical trials. With a focus on serious infections, the company aims to expand the applications of its existing products, particularly XENLETA, which is being investigated for multiple indications. The market for antibiotics is projected to grow significantly, driven by rising antibiotic resistance and increasing infection rates, presenting a favorable environment for Nabriva's offerings. Additionally, the company's gross margin of 19.9% reflects its operational efficiency, although it faces challenges with a profit margin of -160.3%. Investors should monitor the progress of Nabriva's clinical trials and regulatory submissions as key indicators of future performance.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market Cap: $0.00B, indicating current valuation challenges.
- P/E Ratio: -0.00, reflecting ongoing losses.
- Profit Margin: -160.3%, showing significant operational losses.
- Gross Margin: 19.9%, indicating some level of operational efficiency.
- Beta: -0.84, suggesting lower volatility compared to the market.
Competidores y Pares
Fortalezas
- Strong focus on innovative anti-infective agents.
- Existing FDA-approved products generating initial revenue.
- Experienced leadership team with industry knowledge.
Debilidades
- Current negative profit margin indicating operational challenges.
- Limited product portfolio compared to larger competitors.
- Small workforce may limit operational capacity.
Catalizadores
- Upcoming: Results from ongoing clinical trials for XENLETA in new indications.
- Ongoing: Sales performance of SIVEXTRO and XENLETA in existing markets.
- Upcoming: Potential regulatory submissions for new product indications.
Riesgos
- Potential: Delays in clinical trial results impacting product timelines.
- Ongoing: Competition from larger pharmaceutical companies with more resources.
- Potential: Regulatory challenges that could hinder product approvals.
Oportunidades de crecimiento
- Expansion into Pediatric Markets: Nabriva is advancing XENLETA into Phase I clinical trials for pediatric infections, a segment with significant unmet needs. The pediatric antibiotic market is projected to grow at a CAGR of 6.5%, driven by rising infection rates among children. Successful development could lead to substantial revenue growth.
- Broadening XENLETA Indications: The ongoing clinical trials for XENLETA in treating sexually transmitted infections and cystic fibrosis could open new revenue streams. The global market for cystic fibrosis treatments is expected to reach $15 billion by 2027, providing Nabriva with a lucrative opportunity if XENLETA is approved for these indications.
- Development of CONTEPO: With CONTEPO targeting complicated urinary tract infections, Nabriva is tapping into a market projected to grow significantly. The urinary tract infection treatment market is expected to reach $6 billion by 2025, and successful trials could position Nabriva as a key player in this space.
- Strategic Partnerships: Collaborations with larger pharmaceutical companies for distribution and development could enhance Nabriva's market reach and financial stability. Partnerships can provide additional funding and resources for clinical trials, expediting the development process.
- Regulatory Approvals: Achieving regulatory approvals for its products can significantly enhance Nabriva's market position and revenue potential. The company is actively working on submissions that could lead to market entry and capture a share of the growing antibiotic market.
Oportunidades
- Expansion into pediatric and other unaddressed markets.
- Potential for strategic partnerships to enhance development capabilities.
- Growing global demand for effective antibiotics.
Amenazas
- Intense competition from larger pharmaceutical companies.
- Regulatory hurdles that could delay product approvals.
- Market volatility affecting funding and investment.
Ventajas competitivas
- Innovative product pipeline addressing significant unmet medical needs.
- Established market presence with FDA-approved products.
- Focus on serious infections positions Nabriva uniquely in the biotechnology landscape.
Acerca de NBRVF
Founded in 2005 and headquartered in Dublin, Ireland, Nabriva Therapeutics plc is a biopharmaceutical company dedicated to developing and commercializing novel anti-infective agents aimed at treating serious infections. The company initially operated under the name Nabriva Therapeutics Forschungs GmbH before rebranding in 2007. Nabriva's flagship products include SIVEXTRO, an oxazolidinone-class antibacterial specifically designed for treating acute bacterial skin and skin structure infections (ABSSSI), and XENLETA, a semi-synthetic pleuromutilin antibiotic available for both oral and intravenous administration. Beyond its marketed products, Nabriva is actively pursuing the development of XENLETA for a range of indications, including pediatric infections, sexually transmitted infections, cystic fibrosis, and various forms of pneumonia, among others. The company is also advancing CONTEPO, an epoxide antibiotic targeting complicated urinary tract infections, which is currently in Phase I clinical trials for peri-operative prophylaxis. Nabriva's innovative approach and commitment to addressing unmet medical needs position it as a notable player in the biotechnology sector.
Qué hacen
- Develop and commercialize novel anti-infective agents.
- Market SIVEXTRO for acute bacterial skin infections.
- Market XENLETA for various bacterial infections.
- Conduct clinical trials for new indications of existing products.
- Develop CONTEPO for complicated urinary tract infections.
- Focus on addressing unmet medical needs in serious infections.
Modelo de Negocio
- Generate revenue through the sale of marketed products like SIVEXTRO and XENLETA.
- Pursue additional revenue streams from new product indications and clinical trials.
- Leverage partnerships for co-development and distribution agreements.
Contexto de la Industria
The biotechnology industry is characterized by rapid innovation and significant investment in research and development, particularly in the area of anti-infective agents. The global antibiotic market is expected to grow due to increasing antibiotic resistance and the rising prevalence of infectious diseases. Nabriva Therapeutics plc operates in a competitive landscape with several key players, including BIOCQ, CDXI, ELOX, HTGMQ, and MDVLQ, each focusing on various therapeutic areas. The demand for effective antibiotics continues to rise, presenting opportunities for Nabriva to expand its market presence.
Clientes Clave
- Healthcare providers and hospitals requiring effective anti-infective treatments.
- Pharmaceutical distributors and wholesalers.
- Patients suffering from serious bacterial infections.
Finanzas
Gráfico e información
Precio de la acción de Nabriva Therapeutics plc (NBRVF): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para NBRVF.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para NBRVF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para NBRVF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de NBRVF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Competidores y Pares
Liderazgo: H. Michael Hogan
CEO
H. Michael Hogan has extensive experience in the biopharmaceutical industry, having held various leadership roles in both public and private companies. He has a strong background in drug development and commercialization, with a focus on anti-infective therapies. Hogan holds a degree in Pharmacology and has been instrumental in guiding Nabriva's strategic direction.
Historial: Under Hogan's leadership, Nabriva has successfully launched SIVEXTRO and advanced its product pipeline, positioning the company for future growth. His strategic decisions have focused on expanding clinical trials and exploring new therapeutic areas.
Información del mercado OTC de NBRVF
The OTC Other tier represents stocks that do not meet the listing requirements of major exchanges like NYSE or NASDAQ. These stocks may have lower liquidity and higher volatility, which can affect trading conditions.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosures can lead to uncertainty about the company's performance.
- Lower trading volumes may result in higher volatility and price fluctuations.
- Potential for fraudulent schemes in the OTC market, requiring diligent research.
- Verify the company's financial health and operational metrics.
- Assess the progress of clinical trials and product approvals.
- Research the competitive landscape and market trends.
- Evaluate management's experience and track record.
- Review any available analyst reports or market commentary.
- Established product offerings with FDA approval.
- Presence of experienced leadership with industry expertise.
- Engagement in clinical trials demonstrating commitment to innovation.
NBRVF Preguntas Frecuentes sobre Acciones de Healthcare
¿Cuáles son los factores clave para evaluar NBRVF?
Nabriva Therapeutics plc (NBRVF) actualmente tiene una puntuación IA de 57/100, indicando puntuación moderada. Fortaleza clave: Strong focus on innovative anti-infective agents.. Riesgo principal a monitorear: Potential: Delays in clinical trial results impacting product timelines.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de NBRVF?
NBRVF actualmente puntúa 57/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de NBRVF?
Los precios de NBRVF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre NBRVF?
La cobertura de analistas para NBRVF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en NBRVF?
Las categorías de riesgo para NBRVF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Delays in clinical trial results impacting product timelines.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de NBRVF?
La relación P/E para NBRVF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está NBRVF sobrevalorada o infravalorada?
Determinar si Nabriva Therapeutics plc (NBRVF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de NBRVF?
Nabriva Therapeutics plc (NBRVF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Limited financial information available due to OTC classification.